Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study

Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice

(2016) Vikrant Vijay et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3

(2015) Christopher M. Schaupp et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Heart rate dynamics in doxorubicin-induced cardiomyopathy

(2015) T Lončar-Turukalo et al.   PHYSIOLOGICAL MEASUREMENT

Paradoxically, iron overload does not potentiate doxorubicin-induced cardiotoxicity in vitro in cardiomyocytes and in vivo in mice

(2015) Charles Guenancia et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

NMR-based metabolomics reveals distinct pathways mediated by curcumin in cachexia mice bearing CT26 tumor

(2015) Yang Quan-Jun et al.   RSC Advances

3-Hydroxybutyrate dehydrogenase-2 and ferritin-H synergistically regulate intracellular iron

(2014) Zhuoming Liu et al.   FEBS Journal

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

(2014) Yoshihiko Ichikawa et al.   JOURNAL OF CLINICAL INVESTIGATION

Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity

(2013) Ahmed M. Al-Abd et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A Novel Insight into the Cardiotoxicity of Antineoplastic Drug Doxorubicin

(2013) Zbynek Heger et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice

(2013) Yang Quanjun et al.   Molecular BioSystems

Comparison of Cardiac Troponin I and T, Including the Evaluation of an Ultrasensitive Assay, as Indicators of Doxorubicin-induced Cardiotoxicity

(2013) William J. Reagan et al.   TOXICOLOGIC PATHOLOGY

Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia

(2012) Antonio Ruggiero et al.   International Journal of Clinical Oncology

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems

(2012) Oktay Tacar et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Mechanisms and management of doxorubicin cardiotoxicity

(2011) Y. Shi et al.   HERZ

Challenges and opportunities of metabolomics

(2011) Caroline H. Johnson et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Protective effects of d-3-hydroxybutyrate and propionate during hypoglycemic coma: Clinical and biochemical insights from infant rats

(2011) Peter W. Schutz et al.   MOLECULAR GENETICS AND METABOLISM

Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer

(2011) Barry H. Trachtenberg et al.   PEDIATRIC CARDIOLOGY

Nitric Oxide: A New Biomarker of Doxorubicin Toxicity in Children?

(2011) Elif Guler et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy

(2010) Rui A. Carvalho et al.   TOXICOLOGY

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

(2009) Renske Altena et al.   LANCET ONCOLOGY

Systems toxicology study of doxorubicin on rats using ultra performance liquid chromatography coupled with mass spectrometry based metabolomics

(2009) Jiangshan Wang et al.   Metabolomics